Loading...
BIOC logo

GlaxoSmithKline S.A.ECASE:BIOC Stock Report

Market Cap ج.م39.5b
Share Price
n/a
1Y827.5%
7D-8.0%
1D-4.4%
Portfolio Value
​
View

GlaxoSmithKline S.A.E

CASE:BIOC Stock Report

Market Cap: ج.م39.5b

GlaxoSmithKlineE (BIOC) Stock Overview

Engages in production of pharmaceutical chemicals. More details

BIOC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance4/6
Financial Health3/6
Dividends0/6

Rewards

Earnings grew by 38.7% over the past year

Risk Analysis

Debt is not well covered by operating cash flow

High level of non-cash earnings

Highly volatile share price over the past 3 months compared to the EG market


BIOC Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW460,775 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
460,775 investors already sharing narratives
View all narratives

GlaxoSmithKline S.A.E Competitors

Price History & Performance

Summary of share price highs, lows and changes for GlaxoSmithKlineE
Historical stock prices
Current Share Priceج.م473.00
52 Week Highج.م609.00
52 Week Lowج.م50.70
Beta0.26
1 Month Change300.85%
3 Month Change566.38%
1 Year Change827.45%
3 Year Change1,384.15%
5 Year Change1,375.36%
Change since IPO4,975.11%

Recent News & Updates

Recent updates

Shareholder Returns

BIOCEG PharmaceuticalsEG Market
7D-8.0%-7.5%0.05%
1Y827.5%239.8%62.9%

Return vs Industry: BIOC exceeded the EG Pharmaceuticals industry which returned 249.3% over the past year.

Return vs Market: BIOC exceeded the EG Market which returned 64.2% over the past year.

Price Volatility

Is BIOC's price volatile compared to industry and market?
BIOC volatility
BIOC Average Weekly Movement20.5%
Pharmaceuticals Industry Average Movement8.6%
Market Average Movement5.9%
10% most volatile stocks in EG Market10.4%
10% least volatile stocks in EG Market3.6%

Stable Share Price: BIOC's share price has been volatile over the past 3 months compared to the EG market.

Volatility Over Time: BIOC's weekly volatility has increased from 12% to 20% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1981n/aHeba El Morshedywww.gsk.com/en-gb/contact-us/worldwide/egypt

GlaxoSmithKline S.A.E engages in production of pharmaceutical chemicals. The company is involved in manufacture of general and specialty medicines, and vaccines. GlaxoSmithKline S.A.E was founded in 1981 and is based in New Cairo, Egypt.

GlaxoSmithKline S.A.E Fundamentals Summary

How do GlaxoSmithKlineE's earnings and revenue compare to its market cap?
BIOC fundamental statistics
Market capج.م39.50b
Earnings (TTM)ج.م194.18m
Revenue (TTM)ج.م3.62b
203.4x
P/E Ratio
10.9x
P/S Ratio

Is BIOC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIOC income statement (TTM)
Revenueج.م3.62b
Cost of Revenueج.م2.89b
Gross Profitج.م724.08m
Other Expensesج.م529.91m
Earningsج.م194.18m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)2.33
Gross Margin20.01%
Net Profit Margin5.37%
Debt/Equity Ratio80.0%

How did BIOC perform over the long term?

See historical performance and comparison

Dividends

0.2%
Current Dividend Yield
32%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/19 16:23
End of Day Share Price 2026/08/19 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GlaxoSmithKline S.A.E is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.